Stevens Capital Management LP Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stevens Capital Management LP bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 418 shares of the biopharmaceutical company’s stock, valued at approximately $367,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Private Trust Co. NA grew its position in Regeneron Pharmaceuticals by 30.4% in the third quarter. Private Trust Co. NA now owns 403 shares of the biopharmaceutical company’s stock worth $332,000 after acquiring an additional 94 shares during the period. CX Institutional raised its stake in shares of Regeneron Pharmaceuticals by 10.7% in the 3rd quarter. CX Institutional now owns 311 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 30 shares during the period. Welch Group LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $222,000. Asset Management One Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 0.5% during the 3rd quarter. Asset Management One Co. Ltd. now owns 52,400 shares of the biopharmaceutical company’s stock worth $43,123,000 after purchasing an additional 272 shares during the period. Finally, Ballentine Partners LLC increased its holdings in Regeneron Pharmaceuticals by 39.7% in the 3rd quarter. Ballentine Partners LLC now owns 996 shares of the biopharmaceutical company’s stock valued at $820,000 after purchasing an additional 283 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target for the company. Truist Financial reiterated a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. TD Cowen increased their price target on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays upped their target price on shares of Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 23rd. Finally, Morgan Stanley raised their price target on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research report on Wednesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $977.77.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded down $7.48 during trading hours on Friday, reaching $883.20. The company’s stock had a trading volume of 505,575 shares, compared to its average volume of 491,077. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a market cap of $96.94 billion, a PE ratio of 25.63, a PEG ratio of 2.60 and a beta of 0.11. The company’s 50-day moving average is $949.30 and its two-hundred day moving average is $893.27. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business earned $10.96 earnings per share. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 827 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total value of $793,093.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,325,338. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,325,338. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the sale, the director now directly owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The disclosure for this sale can be found here. In the last three months, insiders sold 11,022 shares of company stock worth $10,552,991. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.